Overactive Bladder Diagnosis and Treatment

Key Symptoms

• The American Urological Association characterizes overactive bladder (OAB) by urinary urgency, frequency, and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathology 1, 2
• Urgency, the hallmark symptom of OAB, is defined as a sudden, compelling desire to pass urine that is difficult to defer, as described by the International Continence Society 1, 2
• Frequency is typically more than seven micturition episodes during waking hours, though this varies based on fluid intake, sleep patterns, and comorbidities, according to the European Association of Urology 2
• Nocturia is characterized by interruption of sleep one or more times because of the need to void, as defined by the National Institute for Health and Care Excellence 3, 2
• Urgency urinary incontinence is involuntary leakage of urine associated with a sudden compelling desire to void, which may or may not be present, as described by the American Urological Association 1, 2

Diagnosis

• OAB is a diagnosis of exclusion requiring careful history, physical examination, and urinalysis to rule out other conditions, as recommended by the European Association of Urology 3, 2
• The diagnosis of OAB can be made when both daytime and nighttime urinary frequency and urgency (with or without urgency incontinence) are self-reported as bothersome, according to the International Continence Society 1
• Useful diagnostic tools include voiding diary to document intake and voiding patterns, as suggested by the American Urological Association 3, 4
• Post-void residual measurement is recommended in patients with obstructive symptoms, history of incontinence or prostatic surgery, and neurologic diagnoses, as recommended by the European Association of Urology 4
• Validated symptom questionnaires can be used to quantify bladder symptoms and treatment response, as described by the National Institute for Health and Care Excellence 4

Differential Diagnosis

• Urinary tract infection requires urinalysis to exclude, as recommended by the American Urological Association 2
• Nocturnal polyuria is characterized by normal or large volume nocturnal voids, unlike the small volume voids in OAB, as described by the International Continence Society 1
• Polydipsia-related frequency can be distinguished using frequency-volume charts, as suggested by the European Association of Urology 1
• Interstitial cystitis/bladder pain syndrome shares frequency and urgency with OAB but includes bladder/pelvic pain, as described by the American Urological Association 1

Treatment Algorithm

• All patients with OAB should be offered behavioral therapies as first-line treatment, as recommended by the American Urological Association 5, 6
• Behavioral approaches include bladder training and delayed voiding, pelvic floor muscle training for urge suppression, fluid management, caffeine reduction, and weight loss, as suggested by the European Association of Urology 7
• If symptoms persist despite behavioral therapies, offer oral medications such as antimuscarinic medications or beta-3 adrenergic agonists, as recommended by the National Institute for Health and Care Excellence 7, 5
• Antimuscarinic medications should be used with caution in patients with post-void residual (PVR) 250-300 mL, as recommended by the American Urological Association 4
• Beta-3 adrenergic agonists are effective as monotherapy and do not appear to significantly increase risk of urinary retention, as described by the European Association of Urology 5

Special Considerations

• For patients with OAB and benign prostatic hyperplasia (BPH), offer monotherapy with antimuscarinic medications or beta-3 agonists, or combination therapy with an alpha blocker and an antimuscarinic medication or beta-3 agonist, as recommended by the American Urological Association 8
• Antimuscarinics and beta-3 agonists are effective as monotherapy and do not appear to significantly increase risk of urinary retention in patients with OAB and BPH, as described by the European Association of Urology 8

Management of Non‑Neurogenic Overactive Bladder in Adults

First‑Line: Behavioral Therapies

• All adult patients with non‑neurogenic overactive bladder should receive behavioral interventions (bladder training, delayed voiding, pelvic‑floor muscle training, fluid‑intake management, avoidance of caffeine/alcohol, weight‑loss counseling for overweight individuals, and treatment of constipation) before or alongside any pharmacologic therapy. 9
• Behavioral therapies are effective, have no adverse drug‑related effects, and are frequently omitted by clinicians who jump directly to medication. 9

Second‑Line: Oral Pharmacologic Therapy (after 4–8 weeks of adequate behavioral therapy)

• Antimuscarinic agents (e.g., solifenacin, oxybutynin, tolterodine, trospium, darifenacin, propiverine) are FDA‑approved for urgency urinary incontinence, urgency, and frequency; common side‑effects include dry mouth, constipation, and blurred vision. 10
• Antimuscarinics should be used cautiously in patients with post‑void residual volumes of 250–300 mL or higher, as they may exacerbate urinary retention. 10
• Prior to initiating antimuscarinics, measurement of post‑void residual is recommended in patients with obstructive symptoms, a history of retention, prostatic enlargement, neurologic disease, or long‑standing diabetes to avoid worsening retention. 9
• Beta‑3 adrenergic agonist mirabegron (25–50 mg once daily) reduces incontinence episodes, urinary frequency, and increases voided volume; a 50 mg dose shows statistically significant improvement within 4 weeks and does not markedly increase the risk of urinary retention compared with antimuscarinics. 10

Third‑Line: Minimally Invasive Therapies (for patients refractory to behavioral and oral treatments)

Intradetrusor OnabotulinumtoxinA Injection

• Offered to carefully selected refractory patients who can perform intermittent self‑catheterization if needed; urinary retention requiring catheterization occurs in ≈ 5 % of treated individuals. 10
• Requires repeat injections as therapeutic effect wanes over time; adverse events include urinary tract infections and elevated post‑void residual volumes. 10

Sacral Neuromodulation (SNS)

• Recommended as a third‑line option for severe OAB that markedly impairs quality of life; benefits generally outweigh risks in appropriately selected, compliant patients. 10

Percutaneous Tibial Nerve Stimulation (PTNS)

• Typical regimen: 30 minutes of stimulation once weekly for 12 weeks; effective as a third‑line option but necessitates ongoing clinic visits to sustain benefit. 10
• Adverse events are uncommon and usually mild. 10

Fourth‑Line: Invasive Surgical Options (rarely needed)

Augmentation Cystoplasty or Urinary Diversion

• Considered only in extremely rare, severe, refractory cases; carries substantial risks such as lifelong need for intermittent self‑catheterization and potential for malignancy; limited evidence supports use in non‑neurogenic OAB. 10

Indwelling Catheters

• Not recommended except as an absolute last resort because of high rates of catheter‑associated urinary tract infections, urethral erosion, and stone formation; absorbent products are preferred, and catheter use may be justified only when incontinence leads to progressive pressure ulcers. 10

Follow‑Up and Monitoring

• Regular follow‑up (at least every 4–8 weeks) is essential to assess treatment adherence, efficacy, side‑effects, and to discuss alternative options; patients should be encouraged to continue the current regimen for 4–8 weeks to determine response. 10
• Use validated symptom questionnaires and voiding diaries to objectively monitor treatment outcomes. 9